The ReGenHeart trial is a randomized, double-blinded, placebo-controlled multicentre phase II study which will be conducted at 6 centres in the EU. The study will evaluate the efficacy and safety of catheter mediated endocardial AdVEGF-D regenerative gene transfer in 180 patients with life-limiting angina pectoris or equivalent symptom despite optimal medical therapy